Why KOD beats the market
Up 3,899% over three years while the S&P 500 rose 58%.
- Its Nov 12 results:
KOD's Quality Score fell 2 points on Fri, Nov 20, to 5. Its quiet day ended (2 chart checks stopped).
Follow KOD's trial news. Pro members can get an alert when Kodiak Sciences files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 3,899% over three years while the S&P 500 rose 58%.
| Holding it back | A $247M loss |
| Latest filing | 8-K, Nov 12 |
Kodiak Gas Services Q3 2026: Record Adjusted EBITDA, Raised Guidance
KOD closed +7.9% that day.
1 more big story on KOD in the past 12 months, for Pro members.
Tue Dec 1: Evercore ISI 9th Annual HealthCONx…Investor conference · date confirmed.
Expected to report Tue Mar 30, after the close
About 2 quarters
No shelf registration or at-the-market program on file in the last three years.
Director BAKER BROS. ADVISORS LP bought 247,090 shares on Nov 5. 6 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means
Well below its recent run. KOD scores 5 today, against a median of 9 over its last 20 recorded sessions.
KOD is #50 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 50 |
Net income over four quarters: KOD -$247M, BEAM -$108M, TWST -$130M, KYMR -$349M.
Expected to report Tue Mar 30, after the close (in 129 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase in R&D expenses in the third quarter of 2026 was primarily driven by increased clinical activities related to our active PEAK/PINNACLE and ALTO studies and increased manufacturing activities to support our Phase 3 programs.”
KOD's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The remaining decrease in G&A expenses was primarily driven by a non-cash non-recurring gain recognized upon termination of one of our Palo Alto, California building leases, in exchange for which we received an option to lease a separate building on the same campus with certain lease incentives.”
From its results filing (SEC filing · Nov 12)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 12, 2026 | +0.0% | +2.7% | -9.6% |
| Aug 13, 2026 | -6.5% | +3.4% | -0.3% |
| May 7, 2026 | -3.7% | -6.1% | -11.4% |
RSI 52.0, MACD below signal, above both averages. Not scored.
One insider bought $181M across 86 filings in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: KOD is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
KOD scores 5 today, which Breakaway calls Below Average. It is #50 of 273 in Biotech by Quality Score, with 3 of 14 chart checks firing. Up 3,899% over three years while the S&P 500 rose 58%. Cash lasts about 2 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
KOD scores 5 today, which Breakaway calls Below Average (0 to 5). That is #50 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind KOD's 5.
One insider bought $181M across 86 filings in the last 6 months. No open-market sales on record. The newest is Baker Bros. Advisors LP, 10% owner, who bought $15M on Nov 4. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.